GLP-1 receptor agonists for secondary prevention after myocardial infarction and stroke in type 2 diabetes: nationwide real-world evidence - Top-Institutions - MDSpire

GLP-1 receptor agonists for secondary prevention after myocardial infarction and stroke in type 2 diabetes: nationwide real-world evidence

  • By

  • Petra Sedova

  • Michal Vrablík

  • Petr Kala

  • Petr Ošťádal

  • Aleš Tichopád

  • Aleš Tomek

  • Robert Mikulik

  • Gleb Donin

  • Simona Littnerová

  • Julia Anna Kent

  • Jiří Jarkovsky

  • Virend K Somers

  • Robert D Brown

  • January 7, 2026

  • 0 min

Share

Top Institutions in Cardiology

Brief introduction explaining scope and methodology.

  • #1

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Cardiology
    • Endocrinology
    • Diabetes Research

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Cardiology
    • Endocrinology
    • Clinical Research

  • #3

    Johns Hopkins Medicine
    Johns Hopkins Medicine

    Baltimore, MD

    Key Differentiators

    • Cardiology
    • Endocrinology
    • Epidemiology

  • #4

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Cardiology
    • Endocrinology
    • Translational Medicine

  • #5

    University of Oxford
    University of Oxford

    Oxford, Oxfordshire

    Key Differentiators

    • Cardiology
    • Endocrinology
    • Population Health

Original Source(s)

GLP-1 receptor agonists for secondary prevention after myocardial infarction and stroke in type 2 diabetes: nationwide real-world evidence

  • by Petra Sedova, Michal Vrablík, Petr Kala, Petr Ošťádal, Aleš Tichopád, Aleš Tomek, Robert Mikulik, Gleb Donin, Simona Littnerová, Julia Anna Kent, Jiří Jarkovsky, Virend K Somers, Robert D Brown

  • January 7, 2026

Related Content

Occludin-mediated barrier dysfunction and its role in cardiovascular and cerebrovascular pathogenesis

Post-stroke insomnia: multidimensional mechanisms, clinical heterogeneity, and toward mechanism-informed, objectively quantified management

Retinal Age as Disease Biomarker

Fundus-based AI screening can indicate “retinal age” of patients, as well as flag systemic disease risks, says new study

  • May 27, 2026

  • 3 min